Angeles Alvarez-Secord, MD
Duke Cancer Center
Topic Presenter
Financial Disclosure
Duke University Health System
Employee
Grants to Duke for research from Abbvie, Aravive, Astra Zeneca, Daiichi Sankyo, Eisai, Ellipses Pharma, Genmab, GSK, I-MAB Biopharma, Immunogen, Karyopharm, Lilly, Merck, OncoQuest/Canaria Bio, Roche/Genentech, Seagen Inc., TORL Biotherapeutics, VBL Therapeutics, and Zentalis; and research grant funding from Astrazeneca, Immunogen, Mersana, Myriad, and Oncoquest
Researcher
Honorarium for Advisory Boards for Abbvie, Astrazeneca, Corcept, Daiichi Sankyo, Eisai, Faeth Therapeutics, Foundation Medicine, Genmab, Gilead, GSK, Histosonics, and Medtronic
Consultant
Uncompensated role as member on Clinical Trial Steering Committees (uncompensated) for the OVAL Trial (VBL Therapeutics), FLORA-5 and FLORA-4 trials (Oncoquest), and RAINFOL02/GOG3107 and RAINFOL03(Genmab)
Professional Service
Participation on the Project Nana Medical Advisory Board and GOG Foundation Board of Directors
Other